A federal appeals court has blocked the mailing of mifepristone, a drug used in medication abortions, under current FDA rules, requiring in-person prescriptions instead. The ruling limits nationwide access via mail and telemedicine but leaves in-clinic dispensing unaffected. It stems from a challenge to FDA changes made during the COVID-19 pandemic.